<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34143346</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-7601</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The European journal of health economics : HEPAC : health economics in prevention and care</Title><ISOAbbreviation>Eur J Health Econ</ISOAbbreviation></Journal><ArticleTitle>The economic burden of amyotrophic lateral sclerosis: a systematic review.</ArticleTitle><Pagination><StartPage>1151</StartPage><EndPage>1166</EndPage><MedlinePgn>1151-1166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10198-021-01328-7</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This systematic review aimed to comprehensively collect and summarise the current body of knowledge regarding the cost-of-illness of amyotrophic lateral sclerosis, to identify cost-driving factors of the disease and to consider the development of costs over the course of disease. Further, the review sought to assess the methodological quality of the selected studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review was performed using the databases MEDLINE, Embase, Cochrane Library and PsycINFO. Studies examining the economic burden of amyotrophic lateral sclerosis on a patient or national level written in English or German published from the year 2001 onwards were included. Additional searches were conducted. Study characteristics and results were extracted and compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In summary, 20 studies were included in this review. Most studies investigated costs per patient, amounting to total costs between &#x20ac;9741&#x20ac; to &#x20ac;114,605. Six studies confirmed a rise in costs with disease progression, peaking close to the death of a patient. National costs for amyotrophic lateral sclerosis varied between &#x20ac;149 million and &#x20ac;1329 million.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Most of these studies suggest the economic burden of amyotrophic lateral sclerosis to be considerable. However, further research is needed to establish a cost-effective health policy in consideration of disease severities.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Achtert</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Applied Health Services Research (inav GmbH), Berlin, Germany. achtert@inav-berlin.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerkemeyer</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Applied Health Services Research (inav GmbH), Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Health Econ</MedlineTA><NlmUniqueID>101134867</NlmUniqueID><ISSNLinking>1618-7598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cost-of-illness</Keyword><Keyword MajorTopicYN="N">Economic burden</Keyword><Keyword MajorTopicYN="N">Healthcare costs</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>18</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34143346</ArticleId><ArticleId IdType="doi">10.1007/s10198-021-01328-7</ArticleId><ArticleId IdType="pii">10.1007/s10198-021-01328-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schlaile, M.P., Knausberg, T., Mueller, M., Zeman, J.: Viral ice buckets: a memetic perspective on the ALS Ice Bucket Challenge&#x2019;s diffusion. Cogn. Syst. Res. 52, 947&#x2013;969 (2018)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cogsys.2018.09.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, R.H., Al-Chalabi, A.: Amyotrophic lateral sclerosis. N Engl J Med 377(2), 162&#x2013;172 (2017). https://doi.org/10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastl, R., Ludolph, A.C.: Amyotrophic lateral sclerosis. Nervenarzt 78(12), 1449&#x2013;1457 (2007). https://doi.org/10.1007/s00115-007-2354-5 . (quiz 1458-1449)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00115-007-2354-5</ArticleId><ArticleId IdType="pubmed">18038122</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo, E., Messina, P., Logroscino, G., Beghi, E., S Group: Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 75(2), 287&#x2013;297 (2014). https://doi.org/10.1002/ana.24096</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24096</ArticleId><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi, E., Logroscino, G., Chio, A., Hardiman, O., Mitchell, D., Swingler, R., Traynor, B.J.: The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta 1762(11&#x2013;12), 1150&#x2013;1157 (2006). https://doi.org/10.1016/j.bbadis.2006.09.008 . (Epub 2006 Sep 29)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.09.008</ArticleId><ArticleId IdType="pubmed">17071060</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino, G., Traynor, B.J., Hardiman, O., Chio, A., Couratier, P., Mitchell, J.D., Swingler, R.J., Beghi, E.: Eurals: descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79(1), 6&#x2013;11 (2008). https://doi.org/10.1136/jnnp.2006.104828</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.104828</ArticleId><ArticleId IdType="pubmed">18079297</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino, G., Traynor, B.J., Hardiman, O., Chio, A., Mitchell, D., Swingler, R.J., Millul, A., Benn, E., Beghi, E.: Eurals: Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81(4), 385&#x2013;390 (2010). https://doi.org/10.1136/jnnp.2009.183525</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chancellor, A.M., Warlow, C.P.: Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 55(12), 1106&#x2013;1115 (1992). https://doi.org/10.1136/jnnp.55.12.1106</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.55.12.1106</ArticleId><ArticleId IdType="pubmed">1479386</ArticleId><ArticleId IdType="pmc">1015320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph, A. (ed.): Motoneuronenerkrankungen, 3rd edn. Springer, Berlin (2011)</Citation></Reference><Reference><Citation>Chio, A., Logroscino, G., Traynor, B.J., Collins, J., Simeone, J.C., Goldstein, L.A., White, L.A.: Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2), 118&#x2013;130 (2013). https://doi.org/10.1159/000351153 . (Epub 2013 Jul 11)</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B.R.: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;Clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J Neurol Sci 124, 96&#x2013;107 (1994). https://doi.org/10.1016/0022-510x(94)90191-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera, L.C., Leigh, P.N.: Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4, 3 (2009). https://doi.org/10.1186/1750-1172-4-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId><ArticleId IdType="pmc">2656493</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, R.G., Mitchell, J.D., Moore, D.H.: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. (3), CD001447 (2012). https://doi.org/10.1002/14651858.CD001447.pub3</Citation></Reference><Reference><Citation>Al-Chalabi, A., Andersen, P.M., Chandran, S., Chio, A., Corcia, P., Couratier, P., Danielsson, O., de Carvalho, M., Desnuelle, C., Grehl, T., Grosskreutz, J., Holmoy, T., Ingre, C., Karlsborg, M., Kleveland, G., Koch, J.C., Koritnik, B., KuzmaKozakiewicz, M., Laaksovirta, H., Ludolph, A., McDermott, C., Meyer, T., Mitre Ropero, B., Mora Pardina, J., Nygren, I., Petri, S., Povedano Panades, M., Salachas, F., Shaw, P., Silani, V., Staaf, G., Svenstrup, K., Talbot, K., Tysnes, O.B., Van Damme, P., van der Kooi, A., Weber, M., Weydt, P., Wolf, J., Hardiman, O., van den Berg, L.H.: July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener 18(7&#x2013;8), 471&#x2013;474 (2017). https://doi.org/10.1080/21678421.2017.1369125 . (Epub 2017 Oct 4)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S.S., Rawicz, A., Rezael, S., Ma, T., Zhang, C., Lin, K.: An eye-Gaze tracking and human computer interface system for people with ALS and other locked-in diseases. J Med Biol Eng 32(2), 111&#x2013;116 (2012)</Citation><ArticleIdList><ArticleId IdType="doi">10.5405/jmbe.836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg, G., Lowe, S.: Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. Pharmacoeconomics 20(6), 367&#x2013;387 (2002). https://doi.org/10.2165/00019053-200220060-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200220060-00002</ArticleId><ArticleId IdType="pubmed">12052096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynford-Thomas, R., Robertson, N.P.: The economic burden of chronic neurological disease. J Neurol 264(11), 2345&#x2013;2347 (2017). https://doi.org/10.1007/s00415-017-8632-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8632-7</ArticleId><ArticleId IdType="pubmed">29038885</ArticleId><ArticleId IdType="pmc">5686245</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Oranisation: Neurological disorders - public health challenges. https://www.who.int/mental_health/neurology/introduction_neuro_disorders_public_h_challenges.pdf?ua=1 (2006). Accessed June 2020</Citation></Reference><Reference><Citation>Fiorentino, G., Esquinas, A.M.: Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending. Amyotroph Lateral Scler Frontotemporal Degener 19(3&#x2013;4), 315&#x2013;316 (2018). https://doi.org/10.1080/21678421.2017.1408126 . (Epub 2017 Nov 30)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1408126</ArticleId><ArticleId IdType="pubmed">29191046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman, M., Zinman, L.: The economic impact of amyotrophic lateral sclerosis: a systematic review. Expert Rev Pharmacoecon Outcomes Res 15(3), 439&#x2013;450 (2015). https://doi.org/10.1586/14737167.2015.1039941 . (Epub 2015 Apr 30)</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737167.2015.1039941</ArticleId><ArticleId IdType="pubmed">25924979</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., P Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10), 1006&#x2013;1012 (2009). https://doi.org/10.1016/j.jclinepi.2009.06.005 . (Epub 2009 Jul 23)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.005</ArticleId><ArticleId IdType="pubmed">19631508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10), e1-34 (2009). https://doi.org/10.1016/j.jclinepi.2009.06.006 . (Epub 2009 Jul 23)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A.: Cochrane Handbook for systematic reviews of interventions version 6.0 (updated July 2019) (2019)</Citation></Reference><Reference><Citation>Kassen&#xe4;rztliche Bundesvereinigung: Online-Version des EBM. https://www.kbv.de/html/online-ebm.php (2020). Accessed June 2020</Citation></Reference><Reference><Citation>Oecd: Purchasing Power Parties (PPP) (2020). https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm . Accessed June 2020</Citation></Reference><Reference><Citation>Statistisches, B.: Harmonisierter Verbraucherpreisindex (2020). https://www.destatis.de/DE/ZahlenFakten/Gesamtwirtschaft-Umwelt/Preise/Verbraucherpreisindizes/Tabellen_/HarmonisierterVerbraucherpreisindex.tml?cms_gtp=146598_slot%253D2 . Accessed June 2020</Citation></Reference><Reference><Citation>Drummond, M.F., Jefferson, T.O.: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ 313(7052), 275&#x2013;283 (1996). https://doi.org/10.1136/bmj.313.7052.275</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.313.7052.275</ArticleId><ArticleId IdType="pubmed">8704542</ArticleId><ArticleId IdType="pmc">2351717</ArticleId></ArticleIdList></Reference><Reference><Citation>Einarson, T.R., Acs, A., Ludwig, C., Panton, U.H.: Economic burden of cardiovascular disease in Type 2 diabetes: a systematic review. Value. Health. 21(7), 881&#x2013;890 (2018). https://doi.org/10.1016/j.jval.2017.12.019 . (Epub 2018 Feb 16)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2017.12.019</ArticleId><ArticleId IdType="pubmed">30005761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelone, F., Specchia, M.L., Veneziano, M.A., Capizzi, S., Bucci, S., Mancuso, A., Ricciardi, W., de Belvis, A.G.: Economic impact of childhood obesity on health systems: a systematic review. Obes. Rev. 13(5), 431&#x2013;440 (2012). https://doi.org/10.1111/j.1467-789X.2011.00968.x . (Epub 2011 Dec 29)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-789X.2011.00968.x</ArticleId><ArticleId IdType="pubmed">22212590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahadori, K., Doyle-Waters, M.M., Marra, C., Lynd, L., Alasaly, K., Swiston, J., FitzGerald, J.M.: Economic burden of asthma: a systematic review. BMC. Pulm. Med. 9, 24 (2009). https://doi.org/10.1186/1471-2466-9-24</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2466-9-24</ArticleId><ArticleId IdType="pubmed">19454036</ArticleId><ArticleId IdType="pmc">2698859</ArticleId></ArticleIdList></Reference><Reference><Citation>Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J., Loder, E., Force, C.T.: Consolidated health economic evaluation reporting standards (CHEERS) statement. BJOG. 120(6), 765&#x2013;770 (2013). https://doi.org/10.1111/1471-0528.12241</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.12241</ArticleId><ArticleId IdType="pubmed">23565948</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers, S., Goossens, M., de Vet, H., van Tulder, M., Ament, A.: Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int. J. Technol. Assess. Health. Care. 21(2), 240&#x2013;245 (2005)</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462305050324</ArticleId></ArticleIdList></Reference><Reference><Citation>Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., Vist, G.E., Falck-Ytter, Y., Meerpohl, J., Norris, S., Guyatt, G.H.: GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 64(4), 401&#x2013;406 (2011). https://doi.org/10.1016/j.jclinepi.2010.07.015 . (Epub 2011 Jan 5)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.07.015</ArticleId><ArticleId IdType="pubmed">21208779</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Steen, I., van den Berg, J.P., Buskens, E., Lindeman, E., van den Berg, L.H.: The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph. Lateral. Scler. 10(1), 27&#x2013;34 (2009). https://doi.org/10.1080/17482960802103131</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802103131</ArticleId><ArticleId IdType="pubmed">18608087</ArticleId></ArticleIdList></Reference><Reference><Citation>Athanasakis, K., Kyriopoulos, I.I., Sideris, M., Rentzos, M., Evdokimidis, J., Kyriopoulos, J.: Investigating the economic burden of ALS in Greece: a cost-of-illness approach. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 16(1&#x2013;2), 63&#x2013;64 (2015). https://doi.org/10.3109/21678421.2014.932384 . (Epub 2014 Jul 14)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.932384</ArticleId><ArticleId IdType="pubmed">25019279</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennum, P., Ibsen, R., Pedersen, S.W., Kjellberg, J.: Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J. Neurol. 260(3), 785&#x2013;793 (2013). https://doi.org/10.1007/s00415-012-6706-0 . (Epub 2012 Oct 27)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6706-0</ArticleId><ArticleId IdType="pubmed">23104122</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkindale, J., Yang, W., Hogan, P.F., Simon, C.J., Zhang, Y., Jain, A., Habeeb-Louks, E.M., Kennedy, A., Cwik, V.A.: Cost of illness for neuromuscular diseases in the United States. Muscle. Nerve. 49(3), 431&#x2013;438 (2014). https://doi.org/10.1002/mus.23942 . (Epub 2014 Jan 28)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23942</ArticleId><ArticleId IdType="pubmed">23836444</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscular Dystrophy, A.: Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the United States (2012). https://www.mda.org/sites/default/files/Cost_Illness_Report_0.pdf</Citation></Reference><Reference><Citation>Lopez-Bastida, J., Perestelo-Perez, L., Monton-Alvarez, F., Serrano-Aguilar, P., Alfonso-Sanchez, J.L.: Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph. Lateral. Scler. 10(4), 237&#x2013;243 (2009). https://doi.org/10.1080/17482960802430781</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802430781</ArticleId><ArticleId IdType="pubmed">18821088</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh, J., An, J.W., Oh, S.I., Oh, K.W., Kim, J.A., Lee, J.S., Kim, S.H.: Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 16(3&#x2013;4), 202&#x2013;208 (2015). https://doi.org/10.3109/21678421.2014.999791 . (Epub 2015 Feb 3)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.999791</ArticleId><ArticleId IdType="pubmed">25646865</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepelmann, K., Winter, Y., Spottke, A.E., Claus, D., Grothe, C., Schroder, R., Heuss, D., Vielhaber, S., Mylius, V., Kiefer, R., Schrank, B., Oertel, W.H., Dodel, R.: Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J. Neurol. 257(1), 15&#x2013;23 (2010). https://doi.org/10.1007/s00415-009-5256-6 . (Epub 2009 Jul 24)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5256-6</ArticleId><ArticleId IdType="pubmed">19629566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schonfelder, E., Osmanovic, A., Muschen, L.H., Petri, S., Schreiber-Katz, O.: Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet. J. Rare. Dis. 15(1), 149 (2020). https://doi.org/10.1186/s13023-020-01413-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01413-9</ArticleId><ArticleId IdType="pubmed">32532288</ArticleId><ArticleId IdType="pmc">7291655</ArticleId></ArticleIdList></Reference><Reference><Citation>Deloitte Access Economics: Economics analysis of motor neurone disease in Australia&#x2013;Report for Motor Neurone Disease Australia (2015). https://www2.deloitte.com/au/en/pages/economics/articles/economic-analysis-motor-neurone-disease-australia.html</Citation></Reference><Reference><Citation>Connolly, S., Heslin, C., Mays, I., Corr, B., Normand, C., Hardiman, O.: Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 16(1&#x2013;2), 58&#x2013;62 (2015). https://doi.org/10.3109/21678421.2014.957322 . (Epub 2014 Oct 6)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.957322</ArticleId><ArticleId IdType="pubmed">25285902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman, M., Dharamshi, C., Zinman, L.: Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 15(5&#x2013;6), 426&#x2013;432 (2014). https://doi.org/10.3109/21678421.2014.932382 . (Epub 2014 Jul 15)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.932382</ArticleId><ArticleId IdType="pubmed">25025935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes de Almeida, J.P., Pinto, A., Pinto, S., Ohana, B., de Carvalho, M.: Economic cost of home-telemonitoring care for BiPAP-assisted ALS individuals. Amyotroph Lateral Scler. 13(6), 533&#x2013;537 (2012). https://doi.org/10.3109/17482968.2012.703675 . (Epub 2012 Aug 8)</Citation></Reference><Reference><Citation>Meng, L., Bian, A., Jordan, S., Wolff, A., Shefner, J.M., Andrews, J.: Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 19(1&#x2013;2), 134&#x2013;142 (2018). https://doi.org/10.1080/21678421.2017.1363242 . (Epub 2017 Sep 11)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1363242</ArticleId><ArticleId IdType="pubmed">28891333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, W., Chen, X., Bao, J., Bai, Y., Lu, H., Wang, Q., Liu, Y., Yuan, C., Li, W., Liu, Z., Liu, J., Zhu, X., Qin, B., Cai, D., Zhou, H.: The use of integrative therapies in patients with amyotrophic lateral sclerosis in shanghai, china. Evid. Based. Complement. Alternat. Med. 2013, 613596 (2013). https://doi.org/10.1155/2013/613596 . (Epub 2013 Dec 2)</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/613596</ArticleId><ArticleId IdType="pubmed">24363770</ArticleId><ArticleId IdType="pmc">3865630</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Institute for Health, I.: The burden of neurological diseases, disorders and injuries in Canada (2007). https://secure.cihi.ca/free_products/BND_e.pdf</Citation></Reference><Reference><Citation>McCabe, M.P., O&#x2019;Connor, E.J.: The Economic impact of progressive neurological ilness on quality of Lige in Australia. J. Fam. Econ. Issues 31(1), 82&#x2013;89 (2010)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10834-009-9177-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Darba, J.: Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: a population-based analysis. PLoS One 14(10), e0223772 (2019). https://doi.org/10.1371/journal.pone.0223772</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0223772</ArticleId><ArticleId IdType="pubmed">31603947</ArticleId><ArticleId IdType="pmc">6788732</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, A., Young, C.A., Hughes, D.A.: Health utilities and costs for motor neurone disease. Value. Health. 22(11), 1257&#x2013;1265 (2019). https://doi.org/10.1016/j.jval.2019.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2019.05.011</ArticleId><ArticleId IdType="pubmed">31708062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwicker, J., Qureshi, D., Talarico, R., Bourque, P., Scott, M., Chin-Yee, N., Tanuseputro, P.: Dying of amyotrophic lateral sclerosis: health care use and cost in the last year of life. Neurology 93(23), e2083&#x2013;e2093 (2019). https://doi.org/10.1212/WNL.0000000000008582</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008582</ArticleId><ArticleId IdType="pubmed">31672715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner, L., Archer, N.P., Williamson, D.M., Henry, J.P., Schiffer, R., Jackson, C.E.: Prevalence of amyotrophic lateral sclerosis in Texas, 1998&#x2013;2003. Tex. Med. 108(5), e1 (2012)</Citation><ArticleIdList><ArticleId IdType="pubmed">22714948</ArticleId></ArticleIdList></Reference><Reference><Citation>Orphanet Report Series: prevalence of rare diseases: Bibliographic data-May 2012-Number 1 (2012). http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf . Accessed June 2020</Citation></Reference><Reference><Citation>ALS Society of Ontario: What is ALS? (2006) http://www.alsont.ca/what_is_als.aspx . Accessed 20 Jun 2006</Citation></Reference><Reference><Citation>Alcaz, S., Jarebinski, M., Pekmezovic, T., Stevic-Marinkovic, Z., Pavlovic, S., Apostolski, S.: Epidemiological and clinical characteristics of ALS in Belgrade Yugoslavia. Acta. Neurol. Scand. 94(4), 264&#x2013;268 (1996). https://doi.org/10.1111/j.1600-0404.1996.tb07063.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1996.tb07063.x</ArticleId><ArticleId IdType="pubmed">8937538</ArticleId></ArticleIdList></Reference><Reference><Citation>Orphanet Report Series: prevalence of rare diseases: Bibliographic data-May 2011-Number 1 (2011). http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf .</Citation></Reference><Reference><Citation>Worms, P.M.: The epidemiology of motor neuron diseases: a review of recent studies. J. Neurol. Sci. 191(1&#x2013;2), 3&#x2013;9 (2001). https://doi.org/10.1016/s0022-510x(01)00630-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(01)00630-x</ArticleId><ArticleId IdType="pubmed">11676986</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin, M., Phukan, J., Bede, P., Jordan, N., Byrne, S., Pender, N., Hardiman, O.: Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 76(14), 1263&#x2013;1269 (2011). https://doi.org/10.1212/WNL.0b013e318214359f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318214359f</ArticleId><ArticleId IdType="pubmed">21464431</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, P.H., Wang, Y., Doorish, C., Lewis, M., Battista, V., Mitsumoto, H., Marder, K.: A screening assessment of cognitive impairment in patients with ALS. Amyotroph. Lateral. Scler. 8(6), 362&#x2013;365 (2007). https://doi.org/10.1080/17482960701500817</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701500817</ArticleId><ArticleId IdType="pubmed">17852014</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong, M.J., Abrahams, S., Goldstein, L.H., Woolley, S., McLaughlin, P., Snowden, J., Mioshi, E., Roberts-South, A., Benatar, M., HortobaGyi, T., Rosenfeld, J., Silani, V., Ince, P.G., Turner, M.R.: Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 18(3&#x2013;4), 153&#x2013;174 (2017). https://doi.org/10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId><ArticleId IdType="pmc">7409990</ArticleId></ArticleIdList></Reference><Reference><Citation>Oecd: Health spending. https://data.oecd.org/healthres/health-spending.htm . Accessed June 2020</Citation></Reference><Reference><Citation>World Health Organization: The impact of health expenditure on households and options for alternative financing (No. EM/RC51/4) (2004)</Citation></Reference><Reference><Citation>World Health Organization: Global spending on health: a World in Transition. No. WHO/HIS/HGF/HFWorkingPaper/19.4 (2019)</Citation></Reference><Reference><Citation>Oecd: Average wages (2020)</Citation></Reference><Reference><Citation>Larg, A., Moss, J.R.: Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 29(8), 653&#x2013;671 (2011). https://doi.org/10.2165/11588380-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11588380-000000000-00000</ArticleId><ArticleId IdType="pubmed">21604822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney, J.P.K., Brayne, C., Tobin, K., Logroscino, G., Glymour, M.M., Hardiman, O.: Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease. Neurology 88(24), 2321&#x2013;2329 (2017). https://doi.org/10.1212/WNL.0000000000004038 . (Epub 2017 May 17)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004038</ArticleId><ArticleId IdType="pubmed">28515268</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman, M.H., de Jong, S.W., van Doormaal, P.T., Weinreich, S.S., Schelhaas, H.J., van der Kooi, A.J., de Visser, M., Veldink, J.H., van den Berg, L.H.: Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J. Neurol. Neurosurg. Psychiatry. 82(10), 1165&#x2013;1170 (2011). https://doi.org/10.1136/jnnp.2011.244939 . (Epub 2011 May 27)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2011.244939</ArticleId><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor, B.J., Codd, M.B., Corr, B., Forde, C., Frost, E., Hardiman, O.: Incidence and prevalence of ALS in Ireland, 1995&#x2013;1997: a population-based study. Neurology 52(3), 504&#x2013;509 (1999). https://doi.org/10.1212/wnl.52.3.504</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.52.3.504</ArticleId><ArticleId IdType="pubmed">10025778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J., Langa, K.M.: Monetary costs of dementia in the United States. N. Engl. J. Med. 368(14), 1326&#x2013;1334 (2013). https://doi.org/10.1056/NEJMsa1204629</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa1204629</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId><ArticleId IdType="pmc">3959992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal, S.L., Dall, T.M., Chakrabarti, R., Storm, M.V., Jain, A.: The current and projected economic burden of Parkinson&#x2019;s disease in the United States. Mov. Disord. 28(3), 311&#x2013;318 (2013). https://doi.org/10.1002/mds.25292 . (Epub 2013 Feb 21)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25292</ArticleId><ArticleId IdType="pubmed">23436720</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa, N., Ferlicoq, L., Derumeaux-Burel, H., Rapp, T., Garnault, V., Gillette-Guyonnet, S., Andrieu, S., Vellas, B., Lamure, M., Grand, A., Molinier, L.: Comparison of informal care time and costs in different age-related dementias: a review. Biomed. Res. Int. 2013, 852368 (2013). https://doi.org/10.1155/2013/852368 . (Epub 2012 Dec 5)</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/852368</ArticleId><ArticleId IdType="pubmed">23509789</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermann, M., Lyon, M.: Financial cost of amyotrophic lateral sclerosis: a case study. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 16(1&#x2013;2), 54&#x2013;57 (2015). https://doi.org/10.3109/21678421.2014.951946 . (Epub 2014 Sep 23)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.951946</ArticleId><ArticleId IdType="pubmed">25245119</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss, A.H., Casey, P., Stocking, C.B., Roos, R.P., Brooks, B.R., Siegler, M.: Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes. Neurology 43(2), 438&#x2013;443 (1993). https://doi.org/10.1212/wnl.43.2.438</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.43.2.438</ArticleId><ArticleId IdType="pubmed">8437718</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, N.H., Gluyas, C., Mathers, S., Hudson, P., Ugalde, A.: &#x201c;A monster that lives in our lives&#x201d;: experiences of caregivers of people with motor neuron disease and identifying avenues for support. BMJ. Support. Palliat. Care. 9(4), e27 (2019). https://doi.org/10.1136/bmjspcare-2015-001057</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjspcare-2015-001057</ArticleId><ArticleId IdType="pubmed">27125270</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver, D.J., Turner, M.R.: Some difficult decisions in ALS/MND. Amyotroph. Lateral. Scler. 11(4), 339&#x2013;343 (2010). https://doi.org/10.3109/17482968.2010.487532</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.487532</ArticleId><ArticleId IdType="pubmed">20550485</ArticleId><ArticleId IdType="pmc">3182548</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio, G.D., Shaw, P.J., Hardiman, O., Ludolph, A.C., Sales Luis, M.L., Silani, V., ALSSG European: Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph. Lateral. Scler. Other. Motor. Neuron. Disord. 2(3), 159&#x2013;164 (2001). https://doi.org/10.1080/146608201753275517</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608201753275517</ArticleId><ArticleId IdType="pubmed">11771773</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver, D.: Ventilation in motor neuron disease: difficult decisions in difficult circumstances. Amyotroph. Lateral. Scler. Other. Motor. Neuron. Disord. 5(1), 6&#x2013;8 (2004). https://doi.org/10.1080/14660820310016615</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310016615</ArticleId><ArticleId IdType="pubmed">15204017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ffski, O. (ed.): Grundformen gesundheits&#xf6;konomischer Evaluationen, 4th edn. Springer, Berlin (2012)</Citation></Reference><Reference><Citation>Song, F., Hooper, L., Loke, Y.K.: Publication bias: what is it? How do we measure it? How do we avoid it? Open. Access. J. Clin. Trials. 2013(5), 71&#x2013;81 (2013)</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OAJCT.S34419</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal, R.: The &#x201c;file drawer problem&#x201d; and tolerance for null results. Psychol. Bull. 86(3), 638&#x2013;641 (1979)</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-2909.86.3.638</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>